ArticleBlood advances2023

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.

Courtney D DiNardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.